Restricted accessResearch articleFirst published online 2020-04
The Monoclonal Antibody NEO-201 Enhances Natural Killer Cell Cytotoxicity Against Tumor Cells Through Blockade of the Inhibitory CEACAM5/CEACAM1 Immune Checkpoint Pathway
Natural killer (NK) cells are essential to innate immunity and participate in cancer immune surveillance. Heterophilic interactions between carcinoembryonic antigen (CEA) on tumor cells and carcinoembryonic antigen-related cell adhesion molecule 1 (CEACAM1) on NK cells inhibit NK cell cytotoxicity against tumor cells. NEO-201 is a humanized IgG1 monoclonal antibody that recognizes members of CEACAM family, expressed specifically on a variety of human carcinoma cell lines and tumor tissues. This investigation was designed to determine whether the binding of NEO-201 with CEACAM5 on tumor cells can block the CEACAM5/CEACAM1 interaction to restore antitumor cytotoxicity of NK cells.
Materials and Methods:
In vitro functional assays, using various human tumor cell lines as target cells and NK-92 cells as effectors, were conducted to assess the ability of NEO-201 to block the interaction between CEACAM5 on tumor cells and CEACAM1 on NK cells to enhance the in vitro killing of tumor cells by NK-92. NK-92 cells were used as a model of direct NK killing of tumor cells because they lack antibody-dependent cellular cytotoxicity activity.
Results:
Expression profiling revealed that various human carcinoma cell lines expressed different levels of CEACAM5+ and NEO-201+ cells. Addition of NEO-201 significantly enhanced NK-92 cell cytotoxicity against highly CEACAM5+/NEO-201+ expressing tumor cells, suggesting that its activity is correlated with the level of CEACAM5+/NEO-201+ expression.
Conclusions:
These findings demonstrate that NEO-201 can block the interaction between CEACAM5 on tumor cells and CEACAM1 on NK cells to reverse CEACAM1-dependent inhibition of NK cytotoxicity.
Get full access to this article
View all access options for this article.
References
1.
YangY. Cancer immunotherapy: Harnessing the immune system to battle cancer. J Clin Invest, 2015; 125:3335.
2.
ZamarronBF, ChenW. Dual roles of immune cells and their factors in cancer development and progression. Int J Biol Sci, 2011; 7:651.
3.
PardollDM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer, 2012; 12:252.
4.
CampoliM, FerrisR, FerroneS, et al.Immunotherapy of malignant disease with tumor antigen-specific monoclonal antibodies. Clin Cancer Res, 2010; 16:11.
5.
O'DaySJ, MaioM, Chiarion-SileniV, et al.Efficacy and safety of ipilimumab monotherapy in patients with pretreated advanced melanoma: A multicenter single-arm phase II study. Ann Oncol, 2010; 21:1712.
6.
KlineJ, GajewskiTF. Clinical development of mAbs to block the PD1 pathway as an immunotherapy for cancer. Curr Opin Investig Drugs, 2010; 11:1354.
7.
KuespertK, PilsS, HauckCR. CEACAMs: Their role in physiology and pathophysiology. Curr Opin Cell Biol, 2006; 18:565.
8.
BonsorDA, GüntherS, BeadenkopfR, et al.Diverse oligomeric states of CEACAM IgV domains. Proc Natl Acad Sci U S A, 2015; 112:13561.
9.
TchoupaAK, SchuhmacherT, HauckCR. Signaling by epithelial members of the CEACAM family—Mucosal docking sites for pathogenic bacteria. Cell Commun Signal, 2014; 12:27.
10.
BlumenthalRD, HansenHJ, GoldenbergDM. Inhibition of adhesion, invasion, and metastasis by antibodies targeting CEACAM6 (NCA-90) and CEACAM5 (Carcinoembryonic Antigen). Cancer Res, 2005; 65:8809.
11.
BlumenthalRD, LeonE, HansenHJ, et al.Expression patterns of CEACAM5 and CEACAM6 in primary and metastatic cancers. BMC Cancer, 2007; 7:2.
12.
TurrizianiM, FantiniM, BenvenutoM, et al.Carcinoembryonic antigen (CEA)-based cancer vaccines: Recent patents and antitumor effects from experimental models to clinical trials. Recent Pat Anticancer Drug Discov, 2012; 7:265.
13.
JohnsonB, MahadevanD. Emerging role and targeting of carcinoembryonic antigen-related cell adhesion molecule 6 (CEACAM6) in human malignancies. Clin Cancer Drugs, 2015; 2:100.
14.
GaoY, WangJ, ZhouY, et al.Evaluation of serum CEA, CA19-9, CA72-4, CA125 and ferritin as diagnostic markers and factors of clinical parameters for colorectal cancer. Sci Rep, 2018; 8:2732.
15.
ZhangY, CaiP, LiL, et al.Co-expression of TIM-3 and CEACAM1 promotes T cell exhaustion in colorectal cancer patients. Int Immunopharmacol, 2017; 43:210.
16.
YuH, YuJ, RenY, et al.Serum CEACAM1 level is associated with diagnosis and prognosis in patients with osteosarcoma. PLoS One, 2016; 11:e0153601.
17.
HosomiS, ChenZ, BakerK, et al.CEACAM1 on activated NK cells inhibits NKG2D-mediated cytolytic function and signaling. Eur J Immunol, 2013; 43:2473.
18.
HelfrichI, SingerBB. Size matters: The functional role of the CEACAM1 isoform signature and its impact for NK cell-mediated killing in melanoma. Cancers (Basel), 2019; 11:E356.
19.
ZeligsK, ArlenPM, TsangK, et al.Abstract 3025: Preclinical characterization of a novel monoclonal antibody targeting a neo-antigen expressed in ovarian and GI malignancies. Cancer Res, 2017; 77:3025.
20.
DavidJM, FantiniM, AnnunziataCM, et al.Abstract 3821: The neoantigen-targeting antibody NEO-201 enhances NK cell-dependent killing of tumor cells through blockade of the inhibitoryCEACAM5/CEACAM1 immune checkpoint pathway. AACR Annual Meeting. April 14–18, 2018. Chicago, Illinois, USA: Proceedings of the American Association for Cancer Research, 2018; 59:980.
21.
FantiniM, DavidJM, SaricO, et al.Preclinical characterization of a novel monoclonal antibody NEO-201 for the treatment of human carcinomas. Front Immunol, 2018; 8:1899.
22.
FantiniM, DavidJM, WongHC, et al.An IL-15 superagonist, ALT-803, enhances antibody-dependent cell-mediated cytotoxicity elicited by the monoclonal antibody NEO-201 against human carcinoma cells. Cancer Biother Radiopharm, 2019; 34:147.
23.
TonnT, BeckerS, EsserR, et al.Cellular immunotherapy of malignancies using the clonal natural killer cell line NK-92. J Hematother Stem Cell Res, 2001; 10:535.
24.
SeidelUJ, SchlegelP, LangP. Natural killer cell mediated antibody-dependent cellular cytotoxicity in tumor immunotherapy with therapeutic antibodies. Front Immunol, 2013; 4:76.
25.
JochemsC, HodgeJW, FantiniM, et al.ADCC employing an NK cell line (haNK) expressing the high affinity CD16 allele with avelumab, an anti-PD-L1 antibody. Int J Cancer, 2017; 141:583.
26.
DunnGP, OldLJ, SchreiberRD. The three Es of cancer immunoediting. Annu Rev Immunol, 2004; 22:329.
27.
LjunggrenHG, MalmbergKJ. Prospects for the use of NK cells in immunotherapy of human cancer. Nat Rev Immunol, 2007; 7:329.
28.
Berrien-ElliottMM, RomeeR, FehnigerTA. Improving natural killer cell cancer immunotherapy. Curr Opin Organ Transplant, 2015; 20:671.
29.
ChenZ, YangY, LiuLL, et al.Strategies to augment natural killer (NK) cell activity against solid tumors. Cancers (Basel), 2019; 11:E1040.
30.
ChengM, ChenY, XiaoW, et al.NK cell-based immunotherapy for malignant diseases. Cell Mol Immunol, 2013; 10:230.
31.
FrazaoA, RethackerL, MessaoudeneM, et al.NKG2D/NKG2-ligand pathway offers new opportunities in cancer treatment. Front Immunol, 2019; 10:661.
32.
DuanS, GuoW, XuZ, et al.Natural killer group 2D receptor and its ligands in cancer immune escape. Mol Cancer, 2019; 18:29.
33.
ZingoniA, MolfettaR, FiondaC, et al.NKG2D and its ligands: “One for All, All for One.”. Front Immunol, 2018; 9:476.
34.
MarkelG, LiebermanN, KatzG, et al.CD66a interactions between human melanoma and NK cells: A novel class I MHC-independent inhibitory mechanism of cytotoxicity. J Immunol, 2002; 168:2803.
35.
ChenZ, ChenL, BakerK, et al.CEACAM1 dampens antitumor immunity by down-regulating NKG2D ligand expression on tumor cells. J Exp Med, 2011; 208:2633.
36.
ShiJF, XuSX, HeP, et al.Expression of carcinoembryonic antigen-related cell adhesion molecule 1 (CEACAM1) and its correlation with angiogenesis in gastric cancer. Pathol Res Pract, 2014; 210:473.
37.
LingY, WangJ, WangL, et al.Roles of CEACAM1 in cell communication and signaling of lung cancer and other diseases. Cancer Metastasis Rev, 2015; 34:347.
38.
WangFF, GuanBX, YangJY, et al.CEACAM1 is overexpressed in oral tumors and related to tumorigenesis. Med Mol Morphol, 2017; 50:42.
39.
DanknerM, Gray-OwenSD, HuangYH, et al.CEACAM1 as a multi-purpose target for cancer immunotherapy. Oncoimmunology, 2017; 6:e1328336.
40.
BeaucheminN, ArabzadehA. Carcinoembryonic antigen-related cell adhesion molecules (CEACAMs) in cancer progression and metastasis. Cancer Metastasis Rev, 2013; 32:643.
41.
SternN, MarkelG, ArnonTI, et al.Carcinoembryonic antigen (CEA) inhibits NK killing via interaction with CEA-related cell adhesion molecule 1. J Immunol, 2005; 174:6692.
42.
GovindanSV, CardilloTM, MoonSJ, et al.CEACAM5-targeted therapy of human colonic and pancreatic cancer xenografts with potent labetuzumab-SN-38 immunoconjugates. Clin Cancer Res, 2009; 15:6052.
43.
SchoffelenR, BoermanOC, GoldenbergDM, et al.Development of an imaging-guided CEA-pretargeted radionuclide treatment of advanced colorectal cancer: First clinical results. Br J Cancer, 2013; 109:934.
44.
DotanE, CohenSJ, StarodubAN, et al.Phase I/II trial of labetuzumab govitecan (anti-CEACAM5/SN-38 antibody-drug conjugate) in patients with refractory or relapsing metastatic colorectal cancer. J Clin Oncol, 2017; 35:3338.
45.
DongW, ShiJ, YuanT, et al.Antibody-drug conjugates of 7-ethyl-10-hydroxycamptothecin: Sacituzumab govitecan and labetuzumab govitecan. Eur J Med Chem, 2019; 167:583.
46.
ZhengC, FengJ, LuD, et al.A novel anti-CEACAM5 monoclonal antibody, CC4, suppresses colorectal tumor growth and enhances NK cells-mediated tumor immunity. PLoS One, 2011; 6:e21146.
47.
ClinicalTrials.gov. (2019. QUILT-3.017: Study of NEO-201 in Solid Tumors. Identifier NCT03476681. Online document at https://clinicaltrials.gov/ct2/show/NCT03476681 Accessed on September12, 2019.
